Creating First in Class Multispecific Antibody Modalities
The bispecific antibodies stream at the PEGS Summit will take you through a review of constructs, to the engineering and platform development all the way to preclinical and clinical data. Newer platforms, innovative approaches and constructs are combining to yield unprecedented efficacy. Don’t miss the most significant forum of the year to hear about new advances in the industry and meet face to face with leaders changing the future of biologics.
Conferences and Training Seminars Include:
May 15-16
Introduction to Bispecific Antibodies
May 16-17
Advancing Bispecific Antibodies and Combination Therapy to the Clinic
May 18-19
Engineering Bispecific Antibodies
Keynote Presentations:
Triggered BispecificsJoAnn A. Suzich, PhD, Head, Research, Immunocore LLC
Antibody-Cytokine Fusions for the Treatment of Difficult-to-Cure Cancer Types: Emerging Clinical ResultsDario Neri, PhD, CEO and CSO, Philogen
View By:
May 13-14
Display of Biologics
Digital Integration in Biotherapeutic Analytics
Difficult-to-Express Proteins
Advances in Immunotherapy
Antibodies for Cancer Therapy
Emerging Indications for Therapeutic Antibodies
Intro to Bispecific Antibodies
Intro to Immunogenicity
Intro to Protein Engineering
May 14-15
Engineering Antibodies
Biophysical Methods
Optimizing Protein Expression
Cell-Based Immunotherapy
Emerging Targets for Oncology and Beyond
Immunogenicity Assessment and Management
mRNA Therapeutics
Intro to Machine Learning for Biologics Design
Antibody Deep Sequencing and Single Cell Analysis Data
Machine Learning Approaches for Protein Engineering
Characterization for Novel Biotherapeutics
Maximizing Protein Production Workflows
In vivo Cell and Gene Engineering
Driving Clinical Success in Antibody-Drug Conjugates
Intro to Bioassays
JoAnn A. Suzich, PhD, Head, Research, Immunocore LLC
Dario Neri, PhD, CEO and CSO, Philogen